Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 77, Issue 2, 2007, Pages 180-187

  Reynolds, L Raymond ^a   Kingsley, Felicia J ^a   Karounos, Dennis G ^a   Tannock, Lisa R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Diabetes mellitus; Insulin glargine; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ISOPROSTANE DERIVATIVE; LIPID; LISINOPRIL; METFORMIN; METOPROLOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; LIPIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 34247574161     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.12.011     Document Type: Article

References (35)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
2. American Diabetes Association, Diabetes Statistics (accessed 7 July 2006, at http://www/doabetes.org/diabetes-statistics/complications.jsp).
3. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 279-286
4. Morrow J.D. The isoprostanes-unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr. Pharm. Des. 12 (2006) 895-902
5. American Diabetes Association. Clinical practice recommendations 2006. Diabetes Care 29 Suppl. 1 (2006) S8
6. Turner R.C., Cull C.A., Frighi V., and Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 (1999) 2005-2012
7. Turner R.C., and Holman R.R. Lessons from UK prospective diabetes study. Diabetes Res. Clin. Pract. 28 Suppl. (1995) S151-S157
8. Ovalle F., and Bell D.S. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 4 (2002) 56-59
9. Zhou Z., Li X., Huang G., Peng J., Yang L., Yan X., et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 21 (2005) 203-208
10. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
11. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89 (2004) 2728-2735
12. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
13. Chu J.W., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M., and Tsao P.S. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab. Vasc. Dis. Res. 2 (2005) 37-41
14. Samaha F.F., Szapary P.O., Iqbal N., Williams M.M., Bloedon L.T., Kochar A., et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 624-630
15. Meisner F., Walcher D., Gizard F., Kapfer X., Huber R., Noak A., et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 845-850
16. Wang G., Wei J., Guan Y., Jin N., Mao J., and Wang X. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 54 (2005) 590-597
17. Dandona P., Aljada A., and Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45 (2002) 924-930
18. Aljada A., Ghanim H., Mohanty P., Kapur N., and Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J. Clin. Endocrinol. Metab. 87 (2002) 1419-1422
19. Chaudhuri A., Janicke D., Wilson M.F., Tripathy D., Garg R., Bandyopadhyay A., et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109 (2004) 849-854
20. Dandona P., Aljada A., Dhindsa S., and Garg R. Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clin. Cornerstone Suppl. 4 (2003) S13-S20
21. Dandona P., Aljada A., Mohanty P., Ghanim H., Hamouda W., Assian E., et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J. Clin. Endocrinol. Metab. 86 (2001) 3257-3265
22. Hansen T.K., Thiel S., Wouters P.J., Christiansen J.S., and Van den Berghe G. Intensive insulin therapy exerts anti-inflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J. Clin. Endocrinol. Metab. 88 (2003) 1082-1088
23. Ovalle F., and Bell D. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr. Pract. 4 (1998) 146-147
24. Rosenstock J., Sugimoto D., Strange P., Stewart J.A., Soltes-Rak E., and Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29 (2006) 554-559
25. Sidhu J.S., Cowan D., and Kaski J.C. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am. J. Cardiol. 94 (2004) 151-156
26. Hetzel J., Balletshofer B., Rittig K., Walcher D., Kratzer W., and Hombach V. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1804-1809
27. Dandona P., Mohanty P., Chaudhuri A., Garg R., and Aljada A. Insulin infusion in acute illness. J. Clin. Invest. 115 (2005) 2069-2072
28. Schaumberg D.A., Glynn R.J., Jenkins A.J., Lyons T.J., Rifai N., Manson J.E., et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 111 (2005) 2446-2453
29. Jain S.K., Nagi D.K., Slavin B.M., Lumb P.J., and Yudkin J.S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetes Med. 10 (1993) 27-32
30. Davi G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
31. van Wijk J.P., de Koning E.J., Martens E.P., and Rabelink T.J. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1744-1749
32. Parulkar A.A., Pendergrass M.L., Granada-Ayala R., Lee T.R., and Fonseca V.A. Nonhypoglycemic effects of thiazolidinediones. Ann. Int. Med. 134 (2001) 61-71
33. Freed M.I., Ratner R., Marcovina S.M., Kreider M.M., Biswas N., Cohen B.R., et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol. 90 (2002) 947-952
34. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368 (2006) 1096-1105
35. Dormandy J.W., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289